Is Foundayo or Wegovy pill better for weight loss?

Their molecules have been tested against each other. ACHIEVE-3 randomized 1,698 adults with type 2 diabetes on metformin to orforglipron 12 or 36 mg or oral semaglutide 7 or 14 mg for 52 weeks. Those are the Rybelsus doses, not the 25 mg Wegovy pill. It measured blood sugar first, and both orforglipron doses lowered HbA1c more than both semaglutide doses. (Rosenstock et al., Lancet 2026.) The 11.1% and 13.6% quoted for Foundayo and Wegovy pill on this page are each drug's own label trial, not this comparison. A trial answers for the doses and the people it enrolled, not for one reader.

Which is cheaper, Foundayo or Wegovy pill?

Neither. Both are $299 a month all-in once titrated, each with its source and the date it was read shown above. A tie on price is the answer here, not a gap in it.

Can you switch between Foundayo and Wegovy pill?

They are different molecules, so this is a change of medication rather than of brand, and the one you move to is started on its own dosing schedule.

← All providers and medications

Foundayo (orforglipron) vs Wegovy pill (oral semaglutide 25 mg)

Verdict

Neither comes out ahead on the axes compared here. Wegovy pill scores higher on the published halfrx formula, 6.5 against 6.3; the formula takes in more than this table does.

Computed from the stored fields, so it moves when a price does. Nothing here is written by hand or by a model.

Which is cheaper, Foundayo (orforglipron) or Wegovy pill (oral semaglutide 25 mg)?

Foundayo (orforglipron) is $149–$349 a month all-in, read from its own page on 2026-09-12; Wegovy pill (oral semaglutide 25 mg) is $149–$299, read from its own page on 2026-09-10. At the maintenance dose both cost the same $299 a month, so price does not decide between them. Label-trial weight loss was 11.1% against 13.6%, from separate trials; the molecules were compared directly in ACHIEVE-3, where orforglipron lowered HbA1c more than oral semaglutide 7 or 14 mg over 52 weeks, in type 2 diabetes. Every axis below is computed from stored fields rather than written by hand, so the comparison moves when a price does. They were last checked on 2026-09-12 and 2026-09-10. Neither carries an FTC action, a state action, a BBB F grade or an FDA warning letter. The published formula scores them 6.3 and 6.5 out of 10, arithmetic over the same stored fields rather than an editor's preference.

Head to head

Foundayo (orforglipron) against Wegovy pill (oral semaglutide 25 mg), one row per axis, with the side that wins each axis marked.
What decides it	Foundayo $149–$349/mo	Wegovy pill $149–$299/mo
Entry priceBoth start at $149/mo.	tied	tied
Regulatory and complaint riskNeither carries a lawsuit, an FDA warning letter or a supply-risk flag.	tied	tied
Average weight loss in trialsFoundayo (orforglipron) reports 11.1% and Wegovy pill (oral semaglutide 25 mg) 13.6%, each from its own label trial, so the higher number is not by itself a better result. The trial that did compare the molecules is ACHIEVE-3 (orforglipron lowered HbA1c more than oral semaglutide 7 or 14 mg over 52 weeks, in type 2 diabetes).	not comparable	not comparable

What the trials, the titration and a year actually say

Axis	Foundayo	Wegovy pill
Mean weight loss in the cited trial	11.1%	13.6%
The trial that figure comes from	ATTAIN-1, Trial 1 on the label, 72 weeks: 11.1% mean weight loss at 17.2 mg against 2.1% on placebo, intention-to-treat.	Study 7 on the label (NCT05564117), 64 weeks: 13.6% mean weight loss on 25 mg once daily against 2.4% on placebo, intention-to-treat.
Maintenance dose	5.5 mg, 9 mg, 14.5 mg or 17.2 mg daily	25 mg once daily
Earliest week you reach it	week 9	week 13
Year one at the published price of every step	$3,188	$3,338

Trial percentages are quoted from the label or the named trial beside them. They are not a head-to-head result: different populations, different durations, different endpoints. That is why the comparison above scores this axis as not comparable rather than awarding it to the higher number. The molecules themselves were compared directly in ACHIEVE-3; the result is in the answers below. The year-one figures walk each titration step at its published price and count the twelve 30-day bottles a year holds. The full arithmetic is published.

Go to Foundayo ↗Go to Wegovy pill ↗

Read the price gap carefully: these two are not the same purchase

These are different molecules — orforglipron against semaglutide — so this is a comparison of two treatments, not of two prices for one.
Against every medication on this site with a verified maintenance price, Foundayo (orforglipron) and Wegovy pill (oral semaglutide 25 mg) are joint 3rd cheapest of 9 — the cheapest of them all is $75.

Eli Lilly

Foundayo (orforglipron)

6.3

$149–$349/mo all-in

verified 2026-09-12

Newly approvedPrice conditional on refill timingBoxed warning

Novo Nordisk

Wegovy pill (oral semaglutide 25 mg)

6.5

$149–$299/mo all-in

verified 2026-09-10

Newly approvedStrict dosing rulesBoxed warning

Foundayo (orforglipron)

Pros

+A daily pill with no injection, no needles and no refrigeration — unlike semaglutide pills it is a small molecule, so there are no food-and-water timing rules to follow.[3]
+$149 a month at the entry dose through LillyDirect — the lowest self-pay price for a branded GLP-1 on this site, matched only by the Wegovy pill's first month.[4]
+11.1% mean weight loss over 72 weeks in ATTAIN-1, intention-to-treat — below the Wegovy tablet's 13.6%, and well above the older oral options.[2]
+Being a small molecule, it is manufactured chemically rather than biologically — supply scales in a way peptide injectables cannot.[3]
+Commercially insured with coverage, Lilly's card can bring it to as little as $25 a month.[1]

Cons

−Approved 1 April 2026, so real-world safety data outside trials is still thin compared with semaglutide's years of use.[2]
−$649 list price if you have no coverage and do not use the LillyDirect self-pay channel.[4]
−Weight loss trails tirzepatide injection, which reaches roughly 20%+ in its pivotal trials.[2]
−Maintenance doses hold their $299 price only while you refill within 45 days; lapse and they are $349.[1]

Sources

Wegovy pill (oral semaglutide 25 mg)

Pros

+13.6% mean weight loss on the label's own 64-week trial, intention-to-treat — the strongest result of any oral weight-loss drug approved to date.[5]
+No injections, no needle disposal, no refrigeration.[4]
+Self-pay from roughly $149/mo direct from Novo Nordisk, against $1,349 list for the injection.[3]
+Same molecule as Wegovy injection, which has years of post-marketing safety data behind it.[4]

Cons

−The $149 headline is the 1.5 mg starting month only. The 4 mg month is $199, and every month from 9 mg up — including the 25 mg dose you stay on — is $299, twice the advertised figure.[1]
−Oral semaglutide has strict dosing conditions — taken on an empty stomach with a small sip of water and nothing else for 30 minutes. Adherence in the real world is worse than in trials, which is why this site uses the label's intention-to-treat 13.6%, counting everyone randomized, and not the 16.6% the paper reports for those who kept taking it.[5]
−Telehealth programs add a membership on top of the drug — Ro and Hims both charge $149 a month on a monthly plan — while Novo sells the pill direct at $149 to $299 depending on dose.
−Its 13.6% in the label's 64-week trial is below the 20.9% tirzepatide reached in SURMOUNT-1 on Zepbound's label; these were separate trials, not a head-to-head.[8]

Sources

Foundayo side effects →Wegovy pill side effects →Foundayo dosage →Wegovy pill dosage →

Comparisons are computed from the fields on each card, not written by hand or by a model, so they change when the data does. Information only, not medical advice. halfrx may earn a commission from some links, which never changes what a comparison says.

Everything on Foundayo

Everything on Wegovy pill

Foundayo against Wegovy pill, answered

Is Foundayo or Wegovy pill better for weight loss?: Their molecules have been tested against each other. ACHIEVE-3 randomized 1,698 adults with type 2 diabetes on metformin to orforglipron 12 or 36 mg or oral semaglutide 7 or 14 mg for 52 weeks. Those are the Rybelsus doses, not the 25 mg Wegovy pill. It measured blood sugar first, and both orforglipron doses lowered HbA1c more than both semaglutide doses. (Rosenstock et al., Lancet 2026.) The 11.1% and 13.6% quoted for Foundayo and Wegovy pill on this page are each drug's own label trial, not this comparison. A trial answers for the doses and the people it enrolled, not for one reader.
Which is cheaper, Foundayo or Wegovy pill?: Neither. Both are $299 a month all-in once titrated, each with its source and the date it was read shown above. A tie on price is the answer here, not a gap in it.
Can you switch between Foundayo and Wegovy pill?: They are different molecules, so this is a change of medication rather than of brand, and the one you move to is started on its own dosing schedule.